Mitch Raponi

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi KRAS mutations predict response to EGFR inhibitors
    Mitch Raponi
    Centocor R and D, 145 King of Prussia Road, Radnor, PA 19086, USA
    Curr Opin Pharmacol 8:413-8. 2008

Detail Information

Publications1

  1. ncbi KRAS mutations predict response to EGFR inhibitors
    Mitch Raponi
    Centocor R and D, 145 King of Prussia Road, Radnor, PA 19086, USA
    Curr Opin Pharmacol 8:413-8. 2008
    ..Recent clinical data have provided substantial evidence that KRAS mutational status should be utilized as a diagnostic marker for predicting that response to anti-EGFR therapies in colorectal and non-small cell lung cancer...